JOINT Corp (NASDAQ:JYNT)
| Market Cap | 96.60M-12.6% |
| Revenue (ttm) | 58.72M+3966.7% |
| Net Income | 4.40M+453.6% |
| EPS | 0.20+402.9% |
| Shares Out | 14.14M |
| PE Ratio | 34.22 |
| Forward PE | 17.82 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 58,586 |
| Open | 6.62 |
| Previous Close | 6.65 |
| Day's Range | 6.62 - 6.89 |
| 52-Week Range | 6.52 - 10.67 |
| Beta | 1.16 |
| Analysts | Buy |
| Price Target | 20.00(+192.83%) |
| Earnings Date | Mar 11, 2027 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About JYNT
The Joint Corp. specializes in the establishment, proprietorship, operation, and overall administration of chiropractic treatment centers. Its business operations are structured into two main divisions: corporate-owned clinics and franchised facilities. The firm employs several strategic models for its expansion and day-to-day functioning, which include direct company ownership, various management agreements, licensing its brand to franchisees, and collaborating with regional development partners. As of March 1, 2022, the company maintained approximately 700 active locations throughout the United States. Founded in 2010, The Joint Corp. maintains its primary corporate headquarters in Scottsdale, Arizona.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
1 firm rating JYNT in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Mar 11, 2027Earnings report
$JYNT stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in JYNT holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by JYNT's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
JYNT Estimated quarterly lobbying spending
Source: U.S. Senate LDA
JYNT Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Franchise Operations | $13.55M | 84.57% |
| IT | $1.58M | 9.85% |
| Franchise and regional developer | $893.88K | 5.58% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New JYNT patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to JYNT from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in JYNT
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $1.84M |
| VXFVanguard Extended Market ETF | $655.37K |
| DFASDimensional - US Small Cap ETF | $404.83K |
| SMLFiShares U.S. Small-Cap Equity Factor ETF | $382.52K |
| DFMCU.S. Micro Cap Portfolio ETF | $203.80K |
| DFACDimensional - US Core Equity 2 ETF | $194.35K |
Estimated from each fund’s disclosed top holdings × AUM
JYNT Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from JYNT’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
Healthcare: 48 sector peers carry a ranked score; this one has no qualifying buying in the window · sector average 67.3